About this Research Topic
The study of tumor genomics and circulating - tumor DNA (ctDNA) has opened new avenues in cancer research, diagnosis, and treatment. When analyzing tumor samples or ctDNA from patients, researchers often come across genetic variations that are classified as variants of unknown significance (VUS). These variants pose a significant challenge as their clinical implications and impact in patient care remain uncertain. Patients with tumor genomics or ctDNA and variants of unknown significance are individuals whose genetic profiles display specific genetic alterations that have not been definitively classified as pathognomonic. These variants may include single-nucleotide changes, insertions, deletions, or other complex genetic rearrangements.
Understanding the clinical significance of these variants is crucial for determining appropriate treatment strategies, as certain variants may impact disease prognosis, therapy response, and hereditary cancer risk assessment. Large-scale collaborations, functional studies, and thorough genomic analyses are being conducted to solve the enigma of these mutations to provide more precise and personalized management for patients. Researchers employ various approaches, including genomic analyses and functional studies, to interpret VUS. The integration of multi-omics data, such as gene expression profiles, can enhance the interpretation of VUS and their potential impact on tumor biology. Patients with tumor genomics or ctDNA bearing VUS stand to benefit from improved risk stratification, personalized treatments, and genetic counselling services. By unravelling the significance of these variants, clinicians aim to optimize patient care and facilitate precision oncology approaches that target specific genetic alterations for improved outcomes in cancer patients.
This Research Topic will only accept Case Report submissions, reports must be original with the aim to significantly advance the field to be considered. All Case Reports should contain “Case Report" in the title to be considered for this Research Topic. We welcome all case reports covering all aspects of Tumor Genomics and ctDNA in Precision Medicine.
Understanding the clinical significance of these variants is crucial for determining appropriate treatment strategies, as certain variants may impact disease prognosis, therapy response, and hereditary cancer risk assessment. Large-scale collaborations, functional studies, and thorough genomic analyses are being conducted to solve the enigma of these mutations to provide more precise and personalized management for patients. Researchers employ various approaches, including genomic analyses and functional studies, to interpret VUS. The integration of multi-omics data, such as gene expression profiles, can enhance the interpretation of VUS and their potential impact on tumor biology. Patients with tumor genomics or ctDNA bearing VUS stand to benefit from improved risk stratification, personalized treatments, and genetic counselling services. By unravelling the significance of these variants, clinicians aim to optimize patient care and facilitate precision oncology approaches that target specific genetic alterations for improved outcomes in cancer patients.
This Research Topic will only accept Case Report submissions, reports must be original with the aim to significantly advance the field to be considered. All Case Reports should contain “Case Report" in the title to be considered for this Research Topic. We welcome all case reports covering all aspects of Tumor Genomics and ctDNA in Precision Medicine.
Keywords: Case Reports, ctDNA, Circulating Tumor DNA, Tumor Genomics, Precision Medicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
